SpaceX Isn't Profitable Yet. Does That Make It a Buy, a Hold, or a Pass?

SpaceX is preparing for a June 12 IPO that could raise up to $75 billion at a roughly $2 trillion valuation, or 107x 2025 sales. The article argues the company remains deeply unprofitable, citing a $6.4 billion AI division operating loss in 2025 and a $4.3 billion net loss in Q1 2026 on $4.7 billion of revenue after xAI was integrated. Despite 33% revenue growth in 2025 and rising Starlink subscribers to 10.3 million, the author recommends avoiding the debut and favoring Rocket Lab and AST SpaceMobile instead.

Analysis

The setup is less about one IPO and more about capital reallocation across the private-to-public space stack. If the deal prices anywhere near the implied multiple, the market is effectively paying peak scarcity value for a business whose earnings profile is being diluted by a structurally loss-making adjacent platform; that is classic late-cycle IPO behavior and usually pressures all listed comparables, at least temporarily, as investors re-rate what growth is "worth" in launch, satellite broadband, and defense-adjacent space names.

The near-term winner is not the issuer but the under-owned second-tier publics that offer similar narrative exposure without the same valuation shock. ASTS benefits if investors use the IPO as a public-market proxy for satellite connectivity but then rotate into the cheaper alternative with less headline risk; the catch is that any sympathy bid is likely to be tactical and short-lived unless subscriber and deployment milestones remain on track over the next 1-2 quarters. NVDA is only indirectly involved, but the broader AI-capex story matters: when investors see a heavily loss-making platform funding AI spend through equity, they tend to become less forgiving on other AI stories with weak near-term FCF conversion.

The main risk is not operational collapse but multiple compression. A high-profile debut can anchor expectations for months: if the stock trades down 15-25% post-pricing, it can reset the entire sector's implied terminal value and force private-market marks lower, which in turn could tighten funding conditions for adjacent companies and slow hiring/capex plans. Conversely, if the deal clears and holds, it could temporarily reopen the IPO window for other high-growth, unprofitable issuers, but that would likely be a liquidity-driven move rather than a durable fundamental endorsement.

The contrarian read is that the market may be overestimating how much capital can absorb a transaction of this scale at that valuation. Extremely large offerings often create their own supply overhang for 30-90 days, especially when the business has mixed profitability and multiple storylines; even supportive sentiment can fade once lockup and insider-sale expectations enter the conversation. That creates a cleaner opportunity in the post-debut dislocation than in the initial print.

Key Decisions for Investors

• Avoid buying the IPO at the print; wait 30-90 days for post-lockup supply and valuation normalization before considering exposure. Risk/reward is asymmetric against entry at peak hype.
• Relative-value long ASTS vs. short a basket of high-multiple space/launch exposure if the IPO prices above the market's comfort zone. Use the trade as a hedge against sector multiple compression over the next 1-2 months.
• If ASTS is already owned, trim into any sympathy rally around the IPO launch window; re-add only after the first earnings/reporting cycle confirms demand resilience.
• Use NVDA only as a sentiment hedge: if the IPO is received cold, consider that a cue to fade speculative AI-capex baskets over the next several weeks, since the market is likely to punish unprofitable AI stories more broadly.
• For aggressive traders, express a post-IPO disappointment view with downside put spreads on the new listing once options are liquid, targeting a 1-2 month horizon where supply overhang typically matters most.